OCUGENIX

ocugenix-logo

Ocugenix is a therapeutics company focused on the development of cancer immunotherapy drugs intended to treat eye diseases. Its cancer immunotherapy drug is a medicine against drug-resistant bacteria, enabling doctors to perform a cancer-related eye treatment.

#People #Financial #Website #More

OCUGENIX

Industry:
Biotechnology Health Care Medical Therapeutics

Founded:
2015-01-01

Address:
Pittsburgh, Pennsylvania, United States

Country:
United States

Website Url:
http://www.ocugenix.com

Total Employee:
1+

Status:
Active

Contact:
412-600-6379

Email Addresses:
[email protected]

Total Funding:
150 K USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Global Site Tag Sitelinks Search Box


Current Employees Featured

not_available_image

Sean McDonald
Sean McDonald President & CEO @ Ocugenix
President & CEO

Investors List

innovation-works_image

Innovation Works

Innovation Works investment in Seed Round - Ocugenix

innovation-works_image

Innovation Works

Innovation Works investment in Seed Round - Ocugenix

innovation-works_image

Innovation Works

Innovation Works investment in Convertible Note - Ocugenix

Official Site Inspections

http://www.ocugenix.com

  • Host name: box5675.bluehost.com
  • IP address: 162.241.252.14
  • Location: Provo United States
  • Latitude: 40.2342
  • Longitude: -111.6442
  • Metro Code: 770
  • Timezone: America/Denver
  • Postal: 84606

Loading ...

More informations about "Ocugenix"

Ocugenix: Therapies for Angio-Fibrotic Disease

Ocugenix was founded by a nationally recognized research team from the University of Pittsburgh Medical Center and is based on over 20 years of NIH-funded research into the molecular mechanisms of wound healing and cellular โ€ฆSee details»

Ocugenix - Crunchbase Company Profile & Funding

Ocugenix is a therapeutics company focused on the development of cancer immunotherapy drugs intended to treat eye diseases. Its cancer โ€ฆSee details»

About - Ocugen

Dr. Kompella is an Ocugen Co-founder and a member of the board. He is a Professor of Pharmaceutical Sciences, Ophthalmology, and Bioengineering at University of Colorado โ€ฆSee details»

Ocugenix Company Profile | Management and Employees List

Ocugenix focuses on developing therapies for angio-fibrotic diseases of the eye by utilizing the body's natural healing mechanisms to reverse chronic inflammation and restore homeostasis. โ€ฆSee details»

Ocugenix 2025 Company Profile: Valuation, Funding

Ocugenix General Information Description. Developer of cancer immunotherapy therapeutics designed for ocular diseases. The company develops immunotherapy small molecule drugs which is a medicine against drug โ€ฆSee details»

Ocugenix Corp. - Drug pipelines, Patents, Clinical trials - Synapse

May 8, 2025 Explore Ocugenix Corp. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 3 news, Technology Platform:Small molecule drug, Drug:OCU-10-C โ€ฆSee details»

Ocugenix - Overview, News & Similar companies | ZoomInfo.com

Ocugenix is a therapeutics company focused on the development of of cancer immunotherapy drug intended to treat eye diseases. Its cancer immunother apy drug is a medicine against โ€ฆSee details»

Ocugenix - 2025 Company Profile, Funding & Competitors - Tracxn

May 8, 2025 Ocugenix has raised $100K in funding from Innovation Works. The company has 16 active competitors, including 8 funded and 1 that has exited. Its top competitors include โ€ฆSee details»

Pitt Startup Check-in: Ocugenix - University of Pittsburgh

Oct 31, 2023 Prior to launching Ocugenix, McDonald enjoyed success as co-founder of Pittsburgh-based Automated Healthcare Inc, the first robotic medication dispensing system for โ€ฆSee details»

Ocugenix Company Profile | Pittsburgh, PA - Dun & Bradstreet

Ocugenix Company Profile | Pittsburgh, PA | Competitors, Financials & Contacts - Dun & BradstreetSee details»

Ocugenix - Funding, Financials, Valuation & Investors - Crunchbase

Ocugenix is a therapeutics company that develops treatments for angio-fibrotic diseases of the eye. New. Resources. ... Experience the new Crunchbase, powered by AI . Experience the โ€ฆSee details»

Ocugenix: Therapies for Angio-Fibrotic Disease

Ocugenix is focused on the development and commercialization of therapeutics for ocular diseases caused by excessive fibrosis and blood vessels in the eye. The Companyโ€™s lead โ€ฆSee details»

Ocugen - Crunchbase Company Profile & Funding

Ocugen is a clinical-stage biopharmaceutical company focused on discoverinOcugen Inc is a clinical-stage biopharmaceutical business focused on discovering, developing, and โ€ฆSee details»

Ocugen Inc. - Patient-Centric Biotechnology

At Ocugen, we are focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. Our โ€ฆSee details»

Ocugenix - Innovation Works

Ocugenix is developing therapies for angio-fibrotic diseases of the eye such as wet macular degeneration and diabetic retinopathy. These diseases are caused by an aberrant wound โ€ฆSee details»

Pitt Startup Check-in: Ocugenix

Oct 31, 2023 While the development journey for Ocugenix has taken several years, this is not atypical as the average drug takes between 10 and 15 years. โ€œWe have been very efficient in โ€ฆSee details»

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase โ€ฆ

MALVERN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (โ€œOcugenโ€ or the โ€œCompanyโ€) (NASDAQ: OCGN), a biotechnology company focused on discovering, โ€ฆSee details»

Ocugenix - Updates, News, Events, Signals & Triggers - Crunchbase

Ocugenix is a therapeutics company that develops treatments for angio-fibrotic diseases of the eye. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. โ€ฆSee details»

Ocugenix - Contacts, Employees, Board Members, Advisors

Ocugenix is a therapeutics company that develops treatments for angio-fibrotic diseases of the eye. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. โ€ฆSee details»

OCU 110 - AdisInsight - Springer

Nov 24, 2023 OCU 110 is a small molecule that selectively activates the CXCR3 pathway, being developed by Ocugenix for the treatment of neovascular age-related macular OCU 110 Next โ€ฆSee details»

linkstock.net © 2022. All rights reserved